Keloids Pipeline Insight
DelveInsight’s, “Keloids - Pipeline Insight, 2022,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Keloids pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Keloids are raised overgrowths of scar tissue that occur at the site of a skin injury. They occur where trauma, surgery, blisters, vaccinations, acne or body piercing have injured the skin. Keloid scars tend to be larger than the original wound itself. They are shiny, smooth and rounded skin elevations that may be pink, purple, or brown. Most types of skin injury can contribute to keloid scarring. Keloids should not be confused with hypertrophic scars, which are raised scars that do not grow beyond the boundaries of the original wound and may reduce over time. A dermatologist diagnoses a keloid on the basis of its appearance and a history of tissue injury, such as surgery, acne or body piercing. Available treatments include: Removal with conventional surgery, Dressings, Corticosteroid injections, Compression, Cryosurgery, Radiation therapy, Laser therapy, and Fluorouracil injections.
"Keloids - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Keloids pipeline landscape is provided which includes the disease overview and Keloids treatment guidelines. The assessment part of the report embraces, in depth Keloids commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Keloids collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Keloids R&D. The therapies under development are focused on novel approaches to treat/improve Keloids.
Keloids Emerging Drugs Chapters
This segment of the Keloids report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Keloids Emerging Drugs
STP705 is a siRNA therapeutic comprising of two oligonucleotides with directly knock down of both TGF-β1 and COX-2 gene expression. The product candidate has received multiple IND approvals from both the US FDA and Chinese NMPA, including treatments of cholangiocarcinoma, nonmelanoma skin cancer, and hypertrophic scar. The drug is in Phase II clinical studies for the treatment of Keloids.
LEM-S401 is a DegradaBALL-siRNA being developed to treat skin fibrosis. LEM-S401 down-regulates the expression of CTGF and downstream genes such as collagen types I and III, which are over-expressed in fibrotic tissues in vitro and in vivo. The drug is in preclinical studies for the treatment of Keloids.
Further product details are provided in the report……..
Keloids: Therapeutic Assessment
This segment of the report provides insights about the different Keloids drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 4+ key companies which are developing the therapies for Keloids. The companies which have their Keloids drug candidates in the most advanced stage, i.e. Phase II include, Sirnaomics.
DelveInsight’s report covers around 4+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Keloids pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Keloids: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Keloids therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Keloids drugs.
Keloids Report Insights
- Keloids Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Keloids Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Keloids drugs?
- How many Keloids drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Keloids?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Keloids therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Keloids and their status?
- What are the key designations that have been granted to the emerging drugs?